Amendments to the Claims:

Please add new claim 40. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1. – 13. (Canceled)

Claim 14. (Currently Amended) A multilaminate backing construction for labeling and reducing drug abuse potential of ~~use with a primary drug reservoir in~~ a drug delivery device to skin, the construction comprising:

(a) an outer layer comprising an embossable, writable and breathable material, wherein the outer layer is embossed by applying pressure;

(b) a multilaminate tie layer disposed on ~~the~~ a skin proximal surface of the outer layer, ~~wherein~~ the tie layer comprising ~~es~~ a protective barrier to pressure sensitive adhesives, and a secondary drug-containing reservoir layer~~, the secondary drug being a different drug from the primary drug, the tie layer having a polymer such that no adhesive enters the breathable material as part of the breathable material being crushed during embossment~~; and

(c) a base layer disposed on ~~the~~ a skin proximal surface of the tie layer, the base layer being impermeable to the secondary drug thereby preventing permeation thereof to the skin when the drug delivery device is in use;

wherein the protective barrier prevents a pressure sensitive adhesive that adheres the multilaminate backing construction ~~is at the top of a transdermal~~ to the drug delivery device and is external of the outer layer from intruding into the outer layer so that embossability of the outer layer is maintained, ~~such that the base layer of the multilaminate backing construction does not contact the skin when the device is in use.~~

Claim 15. (Currently Amended) The multilaminate backing construction of claim 14 wherein the multilaminate tie layer comprises:

(i) a first layer disposed on ~~the~~ a skin proximal surface of the outer layer;

(ii) a second layer disposed on ~~the~~ a skin proximal surface of the first layer and in composition different from the first layer;

(iii) a third layer disposed on ~~the~~ a skin proximal surface of the second layer and in composition different from the second layer; and

(iv) the secondary drug-containing reservoir.

Claim 16. (Currently Amended) The multilaminate backing construction of claim 15 wherein the first layer is ethylene-vinyl acetate copolymer (EVA) or low density polyethylene (LDPE) layer; the second layer is a polyethylene terephthalate (PET) layer; the third layer is ethylene-vinyl acetate copolymer (EVA)[[;]], low density polyethylene (LDPE) layer, or a polyurethane layer.

Claim 17. (Canceled)

Claim 18. (Previously Presented) The multilaminate backing construction of claim 14 wherein the outer layer comprises a material selected from the group consisting of low density polyethylene (LDPE), medium density polyethylene (MDPE), high density polyethylene (HDPE), ultra high density polyethylene (UHDPE), polypropylene, and polyester.

Claim 19. (Previously Presented) The multilaminate backing construction of claim 14 wherein the base layer comprises a polymeric material selected from the group consisting of polyester-polyolefin laminate, low density polyethylene (LDPE), medium density polyethylene (MDPE), high density polyethylene (HDPE), ethylene methyl acrylate copolymer (EMA), ethylene ethyl acrylate copolymer (EEA), and ethylene butyl acrylate copolymer (EBA) copolymers.

Claim 20. (Previously Presented) The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug and the secondary drug-containing reservoir has a polymeric matrix including an antagonist to the drug.

Claim 21. (Currently Amended) The multilaminate backing construction of claim 14 wherein the ~~multilaminate~~ multilaminate backing is part of a device for transdermal delivery of a drug and the secondary drug-containing reservoir has a thermoformable polymeric matrix including an antagonist to the drug, the antagonist being dispersed in the polymeric matrix but not dissolved in the polymeric matrix.

Claim 22. (Currently Amended) The multilaminate backing construction of claim 14 wherein the ~~multilaminate~~ multilaminate backing is part of a device for transdermal delivery of a drug and wherein the secondary drug-containing reservoir has a polymeric matrix and dispersed in the polymeric matrix is a particulate antagonist to the drug.

Claim 23. (Currently Amended) The multilaminate backing construction of claim 14 wherein the ~~multilaminate~~ multilaminate backing is part of a device for transdermal delivery of a drug to the skin, the secondary drug-containing reservoir includes an antagonist to the drug and wherein the outer layer controls the release of the antagonist.

Claim 24. (Canceled)

Claim 25. (Previously Presented) The multilaminate backing construction of claim 14 wherein the outer layer is made of a material selected from the group consisting of microporous, microfibrullar materials and combinations thereof.

Claim 26. (Previously Presented) The multilaminate backing construction of claim 14 wherein the outer layer is part of a device for transdermal delivery of a drug to the skin, and the secondary drug-containing reservoir contains an antagonist to the drug, the antagonist being selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefene, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof.

Claim 27. (Currently Amended) The multilaminate backing construction of claim 14 wherein the ~~multilaminate~~ multilaminate backing is part of a device for transdermal delivery of a drug to the skin, the secondary drug-containing reservoir includes an antagonist to the drug and wherein the outer layer is microporous and controls the release of the antagonist and the base layer is not permeable to the antagonist such that the antagonist is not delivered to the skin.

Claim 28. (Currently Amended) The multilaminate backing construction of claim 14 wherein the multilaminate tie layer comprises:

(i) a first layer disposed on ~~the~~ a skin proximal surface of the outer layer;

(ii) a second layer disposed on ~~the~~ a skin proximal surface of the first layer and in composition different from the first layer;

(iii) a third layer disposed on ~~the~~ a skin proximal surface of the second layer and in composition different from the second layer; and

(iv) a secondary drug-containing reservoir containing particles of an antagonist to a drug, the particles dispersed in a polymeric matrix in the drug-containing reservoir;

wherein the multilaminate backing construction is part of a device for delivery of the drug and outer layer controls release of the antagonist for deterrence against drug abuse and wherein the embossable outer layer is microporous and not laminated on a layer that is one of a pressure sensitive adhesive and a high density polyethylene such that the embossable outer layer is not permanently clear.

Claim 29. (Previously Presented) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes an antagonist that is not permeable through the base layer and wherein the outer layer is an antagonist release rate controlling layer.

Claim 30. (Previously Presented) The multilaminate backing construction of claim 14 wherein the tie layer does not contain pressure sensitive adhesive or high density polyethylene next to the outer layer.

Claim 31. (Currently Amended) A multilaminate backing construction for labeling and reducing drug abuse potential of ~~use with a primary drug reservoir in~~ a drug delivery device to skin, the construction comprising:

(a) an outer layer comprising an embossable, writable and breathable microporous material, the outer layer being rate-controlling to an antagonist of a drug of the drug delivery device, wherein the outer layer is embossed by applying pressure;

(b) a multilaminate tie layer, the tie layer disposed on ~~the~~ a skin proximal surface of the outer layer and including a first layer disposed on the skin proximal surface of the outer layer and at least one additional layer disposed on ~~the~~ a skin proximal surface of the first layer and different in composition from the first layer, a secondary drug-containing reservoir layer being one of the at least one additional layer, the secondary drug-containing reservoir layer including a polymeric matrix with antagonist-containing particles dispersed therein, the antagonist being ~~different from the primary drug and~~ selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefene, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof; the tie layer comprising a protective barrier to pressure sensitive adhesives; ~~having a polymer such that no adhesive enters pores in the breathable microporous material as some of the pores being crushed during embossment;~~ and

(c) a base layer disposed on the skin proximal surface of the tie layer, the base layer being impermeable to the antagonist preventing permeation thereof to the skin when the drug delivery device is in use;

wherein the protective barrier prevents a pressure sensitive adhesive that adheres the multilaminate backing construction ~~is at the top of a transdermal~~ to the drug delivery device and is external of the outer layer from intruding into the outer layer so that embossability of the outer layer is maintained, ~~such that the base layer of the multilaminate backing construction does not contact the skin when the device is in use.~~

Claim 32. (Currently Amended) The multilaminate backing construction of claim 14 wherein the ~~multilaminate~~ multilaminate tie layer has at least two layers of different materials.

Claims 33. to 39. (Canceled)

Claim 40. (New) The backing construction of claim 14, wherein the tie layer comprises a material having a sufficiently low melting point to permit laminating the tie layer to the outer layer at a temperature, at which the secondary drug is not degraded.